Search

Target validation of agents or combinations of agents in cell culture in one or more murine and human tumor cell lines or mouse embryonic fibroblasts (MEFs) of various genotypes (see below). Use of several different assays depending upon the agent and type of information sought. Availability of an...

Providing Expertise in Design and Implementation of Pre-clinical Trials in Mouse Models This facility will work as a resource specializing in preclinical testing in GEMs (genetically engineered mouse models) for investigators with preliminary evidence that an agent or a combination of drugs may...

Agents alone or in combination will be evaluated in vivo in human tumor xenografts in mice, as well as in GEMs obtained by outsourcing or in-house acquisition when requested. We will evaluate each drug or combination of drugs by different routes or different schedules of administration following...

Improving Human Health Through Preclinical Trials in Mouse Models of Human Disease The goal of our facility, which is partially funded by Dana Farber/Harvard Cancer Center, is to provide expertise in the design and implementation of preclinical trials to test new drugs, drug combinations and novel...

Proper Citation Beth Israel Deaconess Medical Center - Preclinical Murine Pharmacogenetics Facility, RRID: SCR_026599 From an Idea to Its Realization An investigator has an idea for a new preclinical trial and takes it to Core Director for consultation. The Core Director provides advise in the study...

APL as a Novel Paradigm for Experimental Therapeutics Acute promyelocytic leukemia (APL) is associated with the accumulation in the bone marrow of tumor cells with promyelocytic features and the invariable association with specific reciprocal chromosomal translocations involving the retinoic acid...